Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
27 Mar 2024
27 Mar 2024
Historique:
received:
05
01
2023
accepted:
15
03
2024
medline:
28
3
2024
pubmed:
28
3
2024
entrez:
28
3
2024
Statut:
epublish
Résumé
Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint). Secondary endpoints included the presence of ctDNA, toxicity, clinical outcomes at 2-years and association of ctDNA and PIS with clinical outcomes. Forty-five women with TNBC and residual invasive disease after standard neoadjuvant chemotherapy were randomized to nivolumab, capecitabine, or the combination. Here we show that a combination of nivolumab plus capecitabine leads to a greater increase in PIS from baseline to week 6 (91%) compared with nivolumab (47%) or capecitabine (53%) alone (log-rank p = 0.08), meeting the pre-specified primary endpoint. In addition, the presence of circulating tumor DNA (ctDNA) is associated with disease recurrence, with no new safety signals in the combination arm. Our results provide efficacy and safety data on this combination in TNBC and support further development of PIS and ctDNA analyses to identify patients at high risk of recurrence.
Identifiants
pubmed: 38538574
doi: 10.1038/s41467-024-46961-x
pii: 10.1038/s41467-024-46961-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2691Informations de copyright
© 2024. The Author(s).
Références
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7–33 (2022).
pubmed: 35020204
doi: 10.3322/caac.21708
Bianchini, G., De Angelis, C., Licata, L. & Gianni, L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat. Rev. Clin. Oncol. 19, 91–113 (2022).
pubmed: 34754128
doi: 10.1038/s41571-021-00565-2
Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429–4434 (2007).
pubmed: 17671126
doi: 10.1158/1078-0432.CCR-06-3045
Lin, N. U. et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118, 5463–5472 (2012).
pubmed: 22544643
doi: 10.1002/cncr.27581
Waks, A. G. & Winer, E. P. Breast cancer treatment: a review. JAMA 321, 288–300 (2019).
pubmed: 30667505
doi: 10.1001/jama.2018.19323
Cortés, J. et al. LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Ann. Oncol. 32, S1289–S1290 https://doi.org/10.1016/j.annonc.2021.08.2089 (2021).
Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164–172 (2014).
pubmed: 24529560
doi: 10.1016/S0140-6736(13)62422-8
Xia, L. Y., Hu, Q. L., Zhang, J., Xu, W. Y. & Li, X. S. Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases. World J. Surg. Oncol. 18, 129 (2020).
pubmed: 32539858
pmcid: 7296918
doi: 10.1186/s12957-020-01907-7
Bellon, J. R., Burstein, H. J., Frank, E. S., Mittendorf, E. A. & King, T. A. Multidisciplinary considerations in the treatment of triple-negative breast cancer. CA Cancer J. Clin. 70, 432–442 (2020).
pubmed: 32986241
doi: 10.3322/caac.21643
von Minckwitz, G. et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. 30, 1796–1804 (2012).
doi: 10.1200/JCO.2011.38.8595
Spring, L. M. et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin. Cancer Res. 26, 2838–2848 (2020).
pubmed: 32046998
pmcid: 7299787
doi: 10.1158/1078-0432.CCR-19-3492
Fisher, C. S. et al. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response. Ann. Surg. Oncol. 19, 253–258 (2012).
pubmed: 21725686
doi: 10.1245/s10434-011-1877-y
Masuda, N. et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N. Engl. J. Med. 376, 2147–2159 (2017).
pubmed: 28564564
doi: 10.1056/NEJMoa1612645
Mayer, I. A. et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. J. Clin. Oncol. 39, 2539–2551 (2021).
pubmed: 34092112
pmcid: 8577688
doi: 10.1200/JCO.21.00976
Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810–821 (2020).
pubmed: 32101663
doi: 10.1056/NEJMoa1910549
Peter Schmid, J. C. et al. in ESMO Virtual Plenary.
Schmid, P. C. J., et al. in San Antonio Breast Cancer Symposium.
Page, D. B. et al. Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC). J. Clin. Oncol. 36, 1033–1033 (2018).
doi: 10.1200/JCO.2018.36.15_suppl.1033
Page, D. et al. Abstract P2-09-03: updated efficacy of first or second-line pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC) and correlations with baseline lymphocyte and naïve CD4+ T-cell count. Cancer Res. 79, P2-09-03–P02-09-03 (2019).
doi: 10.1158/1538-7445.SABCS18-P2-09-03
Pusztai, L. et al. Abstract OT1-02-04: SWOG S1418/NRG -BR006: a randomized, phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with > 1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapy. Cancer Res. 78, OT1-02-04–OT01-02-04 (2018).
doi: 10.1158/1538-7445.SABCS17-OT1-02-04
Conte, P. F. et al. Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial. J. Clin. Oncol. 38, TPS598–TPS598 (2020).
doi: 10.1200/JCO.2020.38.15_suppl.TPS598
El Bairi, K. et al. The tale of TILs in breast cancer: a report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer 7, 150 (2021).
pubmed: 34853355
pmcid: 8636568
doi: 10.1038/s41523-021-00346-1
Galon, J. et al. Cancer classification using the Immunoscore: a worldwide task force. J. Transl. Med. 10, 205 (2012).
pubmed: 23034130
pmcid: 3554496
doi: 10.1186/1479-5876-10-205
Ortolan, E. et al. Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy. ESMO Open 6, 100086 (2021).
pubmed: 33743331
pmcid: 8010400
doi: 10.1016/j.esmoop.2021.100086
Chen, Y. H. et al. Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy. NPJ Breast Cancer 3, 24 (2017).
pubmed: 28685160
pmcid: 5495776
doi: 10.1038/s41523-017-0028-4
Garcia-Murillas, I. et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol. 5, 1473–1478 (2019).
pubmed: 31369045
pmcid: 6681568
doi: 10.1001/jamaoncol.2019.1838
Magbanua, M. J. M. et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann. Oncol. 32, 229–239 (2021).
pubmed: 33232761
doi: 10.1016/j.annonc.2020.11.007
Parsons, H. A. et al. Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. Clin. Cancer Res. 26, 2556–2564 (2020).
pubmed: 32170028
pmcid: 7654718
doi: 10.1158/1078-0432.CCR-19-3005
Coombes, R. C. et al. Personalized detection of circulating tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin. Cancer Res. 25, 4255–4263 (2019).
pubmed: 30992300
doi: 10.1158/1078-0432.CCR-18-3663
Garcia-Murillas, I. et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 7, 302ra133 (2015).
pubmed: 26311728
doi: 10.1126/scitranslmed.aab0021
McDonald, B. R. et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci. Transl. Med. 11, eaax7392 (2019).
pubmed: 31391323
pmcid: 7236617
doi: 10.1126/scitranslmed.aax7392
Olsson, E. et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol. Med. 7, 1034–1047 (2015).
pubmed: 25987569
pmcid: 4551342
doi: 10.15252/emmm.201404913
Li, Y. et al. Pretreatment neutrophil-to-lymphocyte ratio (NLR) may predict the outcomes of advanced non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). Front Oncol. 10, 654 (2020).
pubmed: 32656072
pmcid: 7324627
doi: 10.3389/fonc.2020.00654
Peng, L. et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol. Immunother. 69, 1813–1822 (2020).
pubmed: 32350592
pmcid: 7413896
doi: 10.1007/s00262-020-02585-w
Kobayashi, T. et al. Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR. Cancer Immunol. Immunother. 71, 461–471 (2022).
pubmed: 34235546
doi: 10.1007/s00262-021-03000-8
Patel, D. A. et al. Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer. Breast Cancer Res. Treat. 174, 443–452 (2019).
pubmed: 30604000
doi: 10.1007/s10549-018-05106-7
Liu, Y., He, M., Wang, C., Zhang, X. & Cai, S. Prognostic value of neutrophil-to-lymphocyte ratio for patients with triple-negative breast cancer: a meta-analysis. Medicine (Baltimore) 101, e29887 (2022).
pubmed: 35839045
doi: 10.1097/MD.0000000000029887
Yuan, S., Liu, Y., Till, B., Song, Y. & Wang, Z. Pretreatment peripheral B cells are associated with tumor response to anti-PD-1-based immunotherapy. Front. Immunol. 11, 563653 (2020).
pubmed: 33162976
pmcid: 7584071
doi: 10.3389/fimmu.2020.563653
Ficial, M. et al. Expression of T-cell exhaustion molecules and human endogenous retroviruses as predictive biomarkers for response to nivolumab in metastatic clear cell renal cell carcinoma. Clin. Cancer Res. 27, 1371–1380 (2021).
pubmed: 33219016
doi: 10.1158/1078-0432.CCR-20-3084
Axelrod, M. L. et al. Peripheral blood monocyte abundance predicts outcomes in patients with breast cancer. Cancer Res. Commun. 2, 286–292 (2022).
pubmed: 36304942
pmcid: 9604512
doi: 10.1158/2767-9764.CRC-22-0023
Larsson, A. M. et al. Peripheral blood mononuclear cell populations correlate with outcome in patients with metastatic breast cancer. Cells 11, 1639 (2022).
pubmed: 35626676
pmcid: 9139201
doi: 10.3390/cells11101639
Farsaci, B. et al. Analyses of pretherapy peripheral immunoscore and response to vaccine therapy. Cancer Immunol. Res. 4, 755–765 (2016).
pubmed: 27485137
pmcid: 5138028
doi: 10.1158/2326-6066.CIR-16-0037
Tsai, Y. T. et al. Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa. J. Immunother. Cancer 10, e004601 (2022).
pubmed: 35418484
pmcid: 9014099
doi: 10.1136/jitc-2022-004601
Li, M., Xu, J., Jiang, C., Zhang, J. & Sun, T. Predictive and prognostic role of peripheral blood T-cell subsets in triple-negative breast cancer. Front Oncol. 12, 842705 (2022).
pubmed: 35242718
pmcid: 8886691
doi: 10.3389/fonc.2022.842705
Egelston, C. et al. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer. J. Immunother. Cancer 9, e002084 (2021).
pubmed: 33757987
pmcid: 7993344
doi: 10.1136/jitc-2020-002084
Padron, L. J. et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat. Med. 28, 1167–1177 (2022).
pubmed: 35662283
pmcid: 9205784
doi: 10.1038/s41591-022-01829-9
Miao, K. et al. Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non-small cell lung cancer. Front Immunol. 13, 912180 (2022).
pubmed: 35844502
pmcid: 9283649
doi: 10.3389/fimmu.2022.912180
Zhang, G. et al. Clinical predictive value of naive and memory T cells in advanced NSCLC. Front. Immunol. 13, 996348 (2022).
pubmed: 36119064
pmcid: 9478592
doi: 10.3389/fimmu.2022.996348
Laza-Briviesca, R. et al. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clin. Transl. Med. 11, e491 (2021).
pubmed: 34323406
pmcid: 8288017
doi: 10.1002/ctm2.491
Lambert, S. L. et al. Association of baseline and pharmacodynamic biomarkers with outcomes in patients treated with the PD-1 inhibitor budigalimab. J. Immunother. 45, 167–179 (2022).
pubmed: 35034046
pmcid: 8906246
doi: 10.1097/CJI.0000000000000408
Olingy, C. et al. CD33 expression on peripheral blood monocytes predicts efficacy of anti-PD-1 immunotherapy against non-small cell lung cancer. Front Immunol. 13, 842653 (2022).
pubmed: 35493454
pmcid: 9046782
doi: 10.3389/fimmu.2022.842653
Jacquelot, N. et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat. Commun. 8, 592 (2017).
pubmed: 28928380
pmcid: 5605517
doi: 10.1038/s41467-017-00608-2
Manjarrez-Orduno, N. et al. Circulating T cell subpopulations correlate with immune responses at the tumor site and clinical response to PD1 inhibition in non-small cell lung cancer. Front Immunol. 9, 1613 (2018).
pubmed: 30123214
pmcid: 6085412
doi: 10.3389/fimmu.2018.01613
Wistuba-Hamprecht, K. et al. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. Eur. J. Cancer 73, 61–70 (2017).
pubmed: 28167454
pmcid: 5599126
doi: 10.1016/j.ejca.2016.12.011
Shevchenko, I. et al. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses. Oncoimmunology 9, 1744946 (2020).
pubmed: 33457090
pmcid: 7790505
doi: 10.1080/2162402X.2020.1744946
Han, J. et al. Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy. Nat. Cancer 2, 300–311 (2021).
pubmed: 34179824
pmcid: 8223731
doi: 10.1038/s43018-021-00180-1
Kamphorst, A. O. et al. Proliferation of PD-1 + CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl. Acad. Sci. USA 114, 4993–4998 (2017).
pubmed: 28446615
pmcid: 5441721
doi: 10.1073/pnas.1705327114
Capone, M. et al. Frequency of circulating CD8 + CD73 + T cells is associated with survival in nivolumab-treated melanoma patients. J. Transl. Med. 18, 121 (2020).
pubmed: 32160899
pmcid: 7065327
doi: 10.1186/s12967-020-02285-0
Gogali, F., Paterakis, G., Rassidakis, G. Z., Liakou, C. I. & Liapi, C. CD3(-)CD16(-)CD56(bright) immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer. Thyroid 23, 1561–1568 (2013).
pubmed: 23721357
doi: 10.1089/thy.2012.0560
Schleypen, J. S. et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin. Cancer Res. 12, 718–725 (2006).
pubmed: 16467081
doi: 10.1158/1078-0432.CCR-05-0857
Kleinewietfeld, M. et al. CD49d provides access to “untouched” human Foxp3+ Treg free of contaminating effector cells. Blood 113, 827–836 (2009).
pubmed: 18941119
doi: 10.1182/blood-2008-04-150524
Kraczyk, B., Remus, R. & Hardt, C. CD49d Treg cells with high suppressive capacity are remarkably less efficient on activated CD45RA- than on naive CD45RA+ Teff cells. Cell Physiol. Biochem. 34, 346–355 (2014).
pubmed: 25060807
doi: 10.1159/000363004
Chen, H. M. et al. Myeloid-derived suppressor cells as an immune parameter in patients with concurrent sunitinib and stereotactic body radiotherapy. Clin. Cancer Res 21, 4073–4085 (2015).
pubmed: 25922428
pmcid: 4720266
doi: 10.1158/1078-0432.CCR-14-2742
Lang, S. et al. Clinical relevance and suppressive capacity of human myeloid-derived suppressor cell subsets. Clin. Cancer Res. 24, 4834–4844 (2018).
pubmed: 29914893
doi: 10.1158/1078-0432.CCR-17-3726
Gazinska, P. et al. Dynamic changes in the NK-, Neutrophil-, and B-cell immunophenotypes relevant in high metastatic risk post neoadjuvant chemotherapy-resistant early breast cancers. Clin. Cancer Res. 28, 4494–4508 (2022).
pubmed: 36161312
pmcid: 9561554
doi: 10.1158/1078-0432.CCR-22-0543
Rallon, N. et al. Expression of PD-1 and Tim-3 markers of T-cell exhaustion is associated with CD4 dynamics during the course of untreated and treated HIV infection. PLoS One 13, e0193829 (2018).
pubmed: 29518102
pmcid: 5843247
doi: 10.1371/journal.pone.0193829
Goggi, J. L. et al. Imaging effector memory T-cells predicts response to PD1-chemotherapy combinations in colon cancer. Biomedicines 10, 2343 (2022).
pubmed: 36289605
pmcid: 9598730
doi: 10.3390/biomedicines10102343
Blackburn, S. D. et al. Coregulation of CD8 + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29–37 (2009).
pubmed: 19043418
doi: 10.1038/ni.1679
Fourcade, J. et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8 + T cell dysfunction in melanoma patients. J. Exp. Med. 207, 2175–2186 (2010).
pubmed: 20819923
pmcid: 2947081
doi: 10.1084/jem.20100637
Sim, G. C. et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J. Clin. Invest 124, 99–110 (2014).
pubmed: 24292706
doi: 10.1172/JCI46266
Maine, C. J. et al. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol. Immunother. 63, 215–224 (2014).
pubmed: 24297569
doi: 10.1007/s00262-013-1503-x
Noman, M. Z. et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211, 781–790 (2014).
pubmed: 24778419
pmcid: 4010891
doi: 10.1084/jem.20131916
Pinheiro, P. F., Justino, G. C. & Marques, M. M. NKp30—a prospective target for new cancer immunotherapy strategies. Br. J. Pharm. 177, 4563–4580 (2020).
doi: 10.1111/bph.15222
Winer, E. P. et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 499–511 (2021).
pubmed: 33676601
doi: 10.1016/S1470-2045(20)30754-3
Shah, A. N. et al. Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer. J. Immunother. Cancer 8, e000173 (2020).
pubmed: 32060053
pmcid: 7057426
doi: 10.1136/jitc-2019-000173
Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27–40 (2021).
pubmed: 34102137
pmcid: 8436782
doi: 10.1016/S0140-6736(21)00797-2
Kim, K. M. et al. Neutrophil to lymphocyte ratio after treatment completion as a potential predictor of survival in patients with triple-negative breast cancer. J. Breast Cancer 24, 443–454 (2021).
pubmed: 34652080
pmcid: 8561138
doi: 10.4048/jbc.2021.24.e43
Xia, Y. et al. The clinical value of the changes of peripheral lymphocyte subsets absolute counts in patients with non-small cell lung cancer. Transl. Oncol. 13, 100849 (2020).
pubmed: 32866935
pmcid: 7475266
doi: 10.1016/j.tranon.2020.100849
Palazon-Carrion, N. et al. Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer. Sci. Rep. 11, 14426 (2021).
pubmed: 34257359
pmcid: 8277895
doi: 10.1038/s41598-021-93838-w
Holl, E. K. et al. Examining peripheral and tumor cellular immunome in patients with cancer. Front Immunol. 10, 1767 (2019).
pubmed: 31417550
pmcid: 6685102
doi: 10.3389/fimmu.2019.01767
Landa, K., Holl, E., Frazier, V., Hwang, E.-S. S. & Nair, S. Understanding the peripheral cellular immunome in patients with breast cancer. J. Clin. Oncol. 37, 7–7 (2019).
doi: 10.1200/JCO.2019.37.8_suppl.7
Foulds, G. A. et al. Immune-phenotyping and transcriptomic profiling of peripheral blood mononuclear cells from patients with breast cancer: identification of a 3 gene signature which predicts relapse of triple negative breast cancer. Front Immunol. 9, 2028 (2018).
pubmed: 30254632
pmcid: 6141692
doi: 10.3389/fimmu.2018.02028
Penack, O. et al. CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia 19, 835–840 (2005).
pubmed: 15744340
doi: 10.1038/sj.leu.2403704
Briceno, P. et al. CD73 ectonucleotidase restrains CD8 + T cell metabolic fitness and anti-tumoral activity. Front Cell Dev. Biol. 9, 638037 (2021).
pubmed: 33681221
pmcid: 7930398
doi: 10.3389/fcell.2021.638037
Du, X. et al. CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1. Proc. Natl. Acad. Sci. USA 115, E11731–E11740 (2018).
pubmed: 30504141
pmcid: 6294892
doi: 10.1073/pnas.1814052115
Peng, Y. P. et al. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer. Oncotarget 7, 66586–66594 (2016).
pubmed: 27626490
pmcid: 5341822
doi: 10.18632/oncotarget.11953
Gumperz, J. E. C. D. 1d-restricted “NKT” cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses? J. Leukoc. Biol. 76, 307–313 (2004).
pubmed: 15123775
doi: 10.1189/jlb.0104038
Curiel, T. J. Tregs and rethinking cancer immunotherapy. J. Clin. Invest 117, 1167–1174 (2007).
pubmed: 17476346
pmcid: 1857250
doi: 10.1172/JCI31202
Liu, J. et al. Research progress on the role of regulatory T cell in tumor microenvironment in the treatment of breast cancer. Front Oncol. 11, 766248 (2021).
pubmed: 34868991
pmcid: 8636122
doi: 10.3389/fonc.2021.766248
Bates, G. J. et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24, 5373–5380 (2006).
pubmed: 17135638
doi: 10.1200/JCO.2006.05.9584
Wang, Q. et al. Changes in T lymphocyte subsets in different tumors before and after radiotherapy: a meta-analysis. Front Immunol. 12, 648652 (2021).
pubmed: 34220806
pmcid: 8242248
doi: 10.3389/fimmu.2021.648652
Heylmann, D., Ponath, V., Kindler, T. & Kaina, B. Comparison of DNA repair and radiosensitivity of different blood cell populations. Sci. Rep. 11, 2478 (2021).
pubmed: 33510180
pmcid: 7843614
doi: 10.1038/s41598-021-81058-1
Yang, F. E. et al. Analysis of weekly complete blood counts in patients receiving standard fractionated partial body radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 33, 617–617 (1995).
pubmed: 7558950
doi: 10.1016/0360-3016(95)00255-W
Jimenez-Cortegana, C., Galassi, C., Klapp, V., Gabrilovich, D. I. & Galluzzi, L. Myeloid-derived suppressor cells and radiotherapy. Cancer Immunol. Res. 10, 545–557 (2022).
pubmed: 35426936
doi: 10.1158/2326-6066.CIR-21-1105
Tachtsidis, A., McInnes, L. M., Jacobsen, N., Thompson, E. W. & Saunders, C. M. Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells. Clin. Exp. Metastasis 33, 521–550 (2016).
pubmed: 27189371
pmcid: 4947105
doi: 10.1007/s10585-016-9796-8
Lipsyc-Sharf, M. et al. Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. J. Clin. Oncol. 40, 2408–2419 (2022).
pubmed: 35658506
pmcid: 9467679
doi: 10.1200/JCO.22.00908
Patel, S. P. et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N. Engl. J. Med 388, 813–823 (2023).
pubmed: 36856617
pmcid: 10410527
doi: 10.1056/NEJMoa2211437
Lepone, L. M. et al. Analyses of 123 peripheral human immune cell subsets: defining differences with age and between healthy donors and cancer patients not detected in analysis of standard immune cell types. J. Circ. Biomark. 5, 5 (2016).
pubmed: 28936253
pmcid: 5548330
doi: 10.5772/62322
Donahue, R. N. et al. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. J. Immunother. Cancer 5, 20 (2017).
pubmed: 28239472
pmcid: 5320726
doi: 10.1186/s40425-017-0220-y
Fang, L. et al. Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade. J. Exp. Clin. Cancer Res. 38, 123 (2019).
pubmed: 30857561
pmcid: 6413451
doi: 10.1186/s13046-019-1126-y
Zelba, H. et al. Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy. Cancer Immunol. Immunother. 67, 1845–1851 (2018).
pubmed: 30218171
doi: 10.1007/s00262-018-2244-7
Flach, S. et al. Liquid BIOpsy for MiNimal RESidual DiSease detection in head and neck squamous cell carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. Br. J. Cancer 126, 1186–1195 (2022).
pubmed: 35132238
pmcid: 9023460
doi: 10.1038/s41416-022-01716-7
Gale, D. et al. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann. Oncol. 33, 500–510 (2022).
pubmed: 35306155
doi: 10.1016/j.annonc.2022.02.007
Plagnol, V. et al. Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling. PLoS One 13, e0193802 (2018).
pubmed: 29543828
pmcid: 5854321
doi: 10.1371/journal.pone.0193802